Why get a NIFTY test?

Available from week 10 of pregnancy, the NIFTY test gives you an early option to know more about the genetic health of your baby.

Compared to traditional screening tests, the NIFTY test offers higher accuracy and lower false positive rates. This means that less women will undergo invasive diagnostic procedures such as amniocentesis or chorionic villus sampling which carry a 1-2% risk of miscarriage.

NIFTY is non-invasive and therefore poses no risk to the mother or baby.

Is the NIFTY Test Right for Me?

The NIFTY test is available to any pregnant woman from the 10th week of pregnancy but is particularly suitable for pregnant women who exhibit certain indications which are highlighted below.

The NIFTY test is suitable if you exhibit any of the following indications:

Maternal age 35 years or older at delivery
Contraindications for invasive prenatal testing, such as placenta prevaria, risk of miscarriage or HBV infection
Fetal ultrasonographic findings indicating an increased risk of aneuploidy
History of a prior pregnancy with a trisomy
Require reassurance following previous screening result
Parental balanced robertsonian translocation with increased risk of fetal trisomy 13 or trisomy 21
Received IVF Treaent or have previosuly suffered from habitual abortion

NSGC (National Society of Genetic Counselors)
The NSGC supports NIPT as an option for patients whose pregnancies are considered to be at an increased risk of certain chromosome abnormalities. Patients whose NIPT results are abnormal, or who have other factors suggestive of a chromosome abnormality, should receive genetic counselling and be given the option of standard confirmatory diagnostic testing.

Testing services for trisomy conditions 21, 18 and 13 are available for twin pregnancies and IVF pregnancies.

Independent validation studies references:

1) Dan S. et al, ‘Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors.’ Prenat. Diagn., 32: 1225–1232. doi: 10.1002/pd.4002
2) Double Blinded Validation Study on 3,464 NIFTY Blood Samples
3) Non-Invasive Prenatal Testing for Trisomy 21, 18 and 13 – Clinical Experience from 146,958 Pregnancies: Published in the Journal of Ultrasound in Obstetrics and Gynecology